ChristopherCannonMD

PubMed

• Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial.
  Rahul Aggarwal, Michael Szarek, Lawrence A Leiter, Renato D Lopes, Michael J Davies, Phillip Banks, Ph Gabriel Steg, Deepak L Bhatt, Christopher P Cannon, Bertram Pitt> ;European Journal of Heart Failure. 2024 Apr 17
• The year in cardiovascular medicine 2023: the top 10 papers in diabetes and metabolic disorders.
  Francesco Cosentino, Christopher Paul Cannon, Nikolaus Marx> ;European Heart Journal. 2024 Apr 7
• 1 citations
  Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease.
  Adam N Berman, David W Biery, Stephanie A Besser, Avinainder Singh, Arthur Shiyovich, Brittany N Weber, Daniel M Huck, Sanjay Divakaran, Jon Hainer, Gurleen Kaur, Mich...> ;Journal of the American College of Cardiology. 2024 Mar 5
• Methods, rationale, and design for a remote pharmacist and navigator-driven disease management program to improve guideline-directed medical therapy in patients with t...
  Alexander J Blood, Lee-Shing Chang, Caitlin Colling, Gretchen Stern, Daniel Gabovitch, Guinevere Feldman, Asma Adan, Fanta Waterman, Emily Durden, Carol Hamersky, Josh...> ;Primary Care Diabetes. 2024 Apr 1
• 1 citations
  Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.
  Rahul Aggarwal, Deepak L Bhatt, Michael Szarek, Christopher P Cannon, Darren K McGuire, Silvio E Inzucchi, Renato D Lopes, Michael J Davies, Phillip Banks, Bertram Pit...> ;Journal of the American College of Cardiology. 2023 Nov 7
• Ticagrelor-Induced Dyspnea: A Controllable Side Effect.
  Gwangsil Kim, Christopher P Cannon> ;JACC. Cardiovascular Interventions. 2023 Oct 23
• Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
  Ambarish Pandey, Ahmed A Kolkailah, Francesco Cosentino, Christopher P Cannon, Robert C Frederich, David Z I Cherney, Samuel Dagogo-Jack, Richard E Pratley, Nilo B Cat...> ;European Heart Journal. 2023 Dec 21
• 1 citations
  Use of Optimal Medical Therapy in Patients With Cardiovascular Disease Undergoing Cardiac Rehabilitation.
  S Hammad Jafri, Pavel Hushcha, Pranav Dorbala, Gisele Bousquet, Christine Lutfy, Lauren Mellett, Lindsay Sonis, Ron Blankstein, Christopher Cannon, Jorge Plutzky, Donn...> ;Current Problems in Cardiology. 2024 Jan 1
• 6 citations
  Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF.
  Bertram Pitt, Deepak L Bhatt, Michael Szarek, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra,...> ;JACC. Heart Failure. 2023 Aug 1
• 5 citations
  Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population.
  Arthur Shiyovich, Adam N Berman, Stephanie A Besser, David W Biery, Daniel M Huck, Brittany Weber, Christopher Cannon, James L Januzzi, John N Booth 3rd, Khurram Nasir...> ;European Heart Journal Open. 2023 Jul 1
• In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?
  Mario Enrico Canonico, Connie N Hess, Christopher P Cannon> ;Current Atherosclerosis Reports. 2023 Jul 1
• 1 citations
  Patients and Their Physician's Perspectives About Oral Anticoagulation in Patients With Atrial Fibrillation Not Receiving an Anticoagulant.
  Christopher P Cannon, Joseph M Kim, Jane J Lee, Julie Sutherland, Ravinder Bachireddy, C Michael Valentine, Steven Hearne, April Trebnick, Sara Jaffer, Sudarshana Datt...> ;JAMA Network Open. 2023 Apr 3
• 3 citations
  Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomi...
  Richard E Pratley, Christopher P Cannon, David Z I Cherney, Francesco Cosentino, Darren K McGuire, Margaret Noyes Essex, David Lawrence, Philip L S Jones, Jie Liu, Ing...> ;The Lancet. Healthy Longevity. 2023 Apr 1
• Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (...
  David Z I Cherney, Francesco Cosentino, Darren K McGuire, Ahmed A Kolkailah, Samuel Dagogo-Jack, Richard E Pratley, Robert Frederich, Mario Maldonado, Chih-Chin Liu, C...> ;Kidney International Reports. 2023 Apr 1
• 7 citations
  Remote Cardiovascular Hypertension Program Enhanced Blood Pressure Control During the COVID-19 Pandemic.
  Simin Gharib Lee, Alexander J Blood, Christopher P Cannon, William J Gordon, Hunter Nichols, David Zelle, Benjamin M Scirica, Naomi D L Fisher> ;Journal of the American Heart Association. 2023 Mar 21
• 4 citations
  Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
  Tae Won Yi, Brendan Smyth, Gian Luca Di Tanna, Clare Arnott, Kathryn Cardoza, Amy Kang, Carol Pollock, Rajiv Agarwal, George Bakris, David M Charytan, Dick de Zeeuw, H...> ;American Journal of Kidney Diseases. 2023 Jul 1
• Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
  Samuel Dagogo-Jack, Robert Frederich, Jie Liu, Christopher P Cannon, Harry Shi, David Z I Cherney, Francesco Cosentino, Urszula Masiukiewicz, Ira Gantz, Richard E Pratley> ;The Journal of Clinical Endocrinology and Metabolism. 2023 Jul 14
• 1 citations
  Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascul...
  Joseph M Kim, Deepak L Bhatt, Samuel Dagogo-Jack, David Z I Cherney, Francesco Cosentino, Darren K McGuire, Richard E Pratley, Chih-Chin Liu, Nilo B Cater, Robert Fred...> ;Diabetes, Obesity & Metabolism. 2023 May 1
• 5 citations
  Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV...
  Karen D Corbin, Samuel Dagogo-Jack, Christopher P Cannon, David Z I Cherney, Francesco Cosentino, Robert Frederich, Jie Liu, Annpey Pong, Jianxin Lin, Nilo B Cater, Ri...> ;Diabetes, Obesity & Metabolism. 2023 Mar 1
• 18 citations
  Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network.
  Alexander J Blood, Christopher P Cannon, William J Gordon, Charlotte Mailly, Taylor MacLean, Samantha Subramaniam, Michela Tucci, Jennifer Crossen, Hunter Nichols, Kav...> ;JAMA Cardiology. 2023 Jan 1
• 2 citations
  Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
  Ashish Sarraju, George Bakris, Christopher P Cannon, David Cherney, C V Damaraju, Gemma A Figtree, Jagadish Gogate, Tom Greene, Hiddo J L Heerspink, James L Januzzi Jr...> ;Journal of the American College of Cardiology. 2022 Nov 1
• 17 citations
  Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.
  Eri Toda Kato, David A Morrow, Jianping Guo, David D Berg, Michael A Blazing, Erin A Bohula, Marc P Bonaca, Christopher P Cannon, James A de Lemos, Robert P Giugliano,...> ;European Heart Journal. 2023 Jan 21
• 3 citations
  Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analy...
  Siddharth M Patel, Arman Qamar, Robert P Giugliano, Petr Jarolim, Nicholas A Marston, Jeong-Gun Park, Michael A Blazing, Christopher P Cannon, Eugene Braunwald, David ...> ;JAMA Cardiology. 2022 Dec 1
• 6 citations
  Individualized therapy in statin intolerance: the key to success.
  Maciej Banach, Christopher P Cannon, Francesco Paneni, Peter E Penson> ;European Heart Journal. 2023 Feb 14
• 2 citations
  A remote hypertension management program clinical algorithm.
  Hunter Nichols, Christopher P Cannon, Benjamin M Scirica, Naomi D L Fisher> ;Clinical Cardiology. 2022 Dec 1
• Join now to see all

Journal Articles

• Dabigatran Dual Therapy with Ticagrelor or Clopidogrel After Percutaneous Coronary Intervention in Atrial Fibrillation Patients with or Without Acute Coronary Syndrome...  
  Christopher P Cannon, Deepak L Bhatt, European Heart Journal

Lectures

• Triple-doubles in Clinical Practice: Should 'Double Therapy' Replace 'Triple therapy' When Anticoagulation and Antiplatelet Therapy are Needed? 
  2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
• Faculty 
  2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
• Frontiers in Prevention 
  2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019